Read more about this disease, some with Classification – Types – Signs and symptoms – Genetics – Pathophysiology – Diagnosis – Screening – Prevention – Treatment and management – Cures and much more, some including pictures and video when available.
Anaplastic thyroid cancer (ATC) (or undifferentiated) is a form of thyroid cancer which has a very poor prognosis (14% ten-year survival rate[1]) due to its aggressive behavior and resistance to cancer treatments.[2]
It rapidly invades surrounding tissues (such as the trachea). The presence of regional lymphadenopathy in older patients in whom FNA reveals characteristic vesicular appearance of the nuclei would support a diagnosis of anaplastic carcinoma.
Unlike its differentiated counterparts, anaplastic thyroid cancer is highly unlikely to be curable either by surgery or by any other treatment modality, and is in fact usually unresectable due to its high propensity for invading surrounding tissues. [3]
Palliative treatment consists of radiation therapy usually combined with chemotherapy.
However, with today’s technology, new drugs, such as combretastatin (fosbretabulin) Bortezomib and TNF-Related Apoptosis Induced Ligand (TRAIL), are being introduced and trialed in clinical labs and human clinical studies. Based on encouraging Phase I and II clinical trial results, with combretastatin (fosbretabulin), a type of drug that selectively destroys tumor blood-vessels, a large, multi-national clinical trial is being undertaken to determine whether the drug can extend the survival of patients with ATC. (For further information see www.thyca.org) Recent studies in Italy have shown positive results against ATC, but more tests outside the lab are needed to confirm this before it can be used in Chemotherapy. There have been some case studies where patients with aggressive Thyroid Cancer have survived outside the mean expected survival time. But the best treatment recommended at this stage is early detection and complete surgery followed by Chemotherapy alongside Radiotherapy for any chance of survival of ATC.
The role of external beam radiotherapy (EBRT) in thyroid cancer remains controversial and there is no level I evidence to recommend it. No published randomised controlled trials have examined the addition of EBRT to standard treatment, namely surgery, radioactive iodine and medical suppression of thyroid stimulating hormones.[4]
Imbalances in age, sex, completeness of surgical excision, histological type and stage, between patients receiving and not receiving EBRT, confound retrospective studies. Variability also exists between treatment and non-treatment groups in the use of radio-iodine and post-treatment thyroid stimulating hormone (TSH) suppression and treatment techniques between and within retrospective studies.
[tubepress mode=’tag’, tagValue=’Anaplastic thyroid cancer’]